Inhibitors of the sodium-glucose cotransporter-2 (SGLT-2) are increasingly used to treat type 2 diabetes and were reported to be positively associated with the risk of bladder cancer (OR = 3.97, 95% CI = 3.39–4.66) (18). The gene discussed is SLC5A2; the disease is urinary bladder cancer.